Waiv, previously known as Owkin Dx, has announced a strategic collaboration with Daiichi Sankyo to enhance biomarker discovery for antibody-drug conjugate (ADC) programs through digital pathology and AI methodologies.
This partnership aims to leverage Waiv's advanced computational pathology platform, which integrates foundation models and AI techniques to analyze early-phase clinical data. The focus will be on tumor microenvironment (TME) analysis using hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained samples. By identifying biomarkers that predict treatment responses, the collaboration seeks to streamline the development of ADCs, potentially improving patient outcomes in oncology.
Waiv's platform is tailored for data-constrained scenarios, employing custom AI models that can derive predictive insights from whole slide images. This innovative approach aims to uncover novel histopathological biomarkers and deliver outputs that are reproducible and interpretable for clinical decision-making.
This collaboration highlights a significant advancement in addressing the challenges of biomarker discovery in oncology, particularly for ADCs, which often require insights from limited patient data. As Waiv continues to refine its capabilities, the partnership with Daiichi Sankyo may pave the way for more effective therapies in cancer treatment, showcasing the transformative potential of AI in the life sciences sector.